Abstract:
The invention relates to compositions and methods for treating inflammatory disorders. More specifically, the invention relates to antibody compositions and their use in the treatment of inflammatory disorders.
Abstract:
The present invention provides a domain antibody construct which binds to human TNF-α, the construct comprising: (a) a domain antibody (dAb) which binds to human TNF-α; (b) a modified hinge region sequence; (c) a human or primate heavy chain constant region sequence having a truncated CH1 domain of not more than 20 residues, wherein said modified hinge region sequence contains either a deletion or a single amino acid substitution of at least one cysteine residue which normally facilitates disulfide bond formation between heavy and light antibody chains.
Abstract translation:本发明提供结合人TNF-α的结构域抗体构建体,所述构建体包含:(a)结合人TNF-α的结构域抗体(dAb); (b)修饰的铰链区序列; (c)具有不超过20个残基的截短C 1 H 1结构域的人或灵长类重链恒定区序列,其中所述修饰的铰链区序列含有缺失或单个氨基酸取代, 至少一个半胱氨酸残基通常促进重和轻抗体链之间的二硫键形成。
Abstract:
The invention relates to compositions and methods for treating inflammatory disorders. More specifically, the invention relates to antibody compositions and their use in the treatment of inflammatory disorders.
Abstract:
The invention provides methods for treating inflammatory diseases (e.g., chronic inflammatory diseases) comprising administering an antagonist of Tumor Necrosis Factor Receptor 1. The invention also provides antagonists of Tumor Necrosis Factor Receptor 1, such as ligands that contain an immunoglobulin single variable domain or domain antibody (dAb) monomer that binds Tumor Necrosis Factor Receptor 1, and methods of using the ligands. Also provided are nucleic acids encoding the ligands, recombinant host cells and methods for preparing the ligands.
Abstract:
The invention relates to compositions and methods for treating inflammatory disorders. More specifically, the invention relates to antibody compositions and their use in the treatment of inflammatory disorders.